Ascendis Pharma A (ASND) Free Cash Flow (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Free Cash Flow data on file, last reported at -$9.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 39.96% year-over-year to -$9.0 million; the trailing twelve-month figure through Mar 2026 stood at -$138.5 million (up 41.05% YoY), and the FY2025 full-year result was -$146.4 million, up 55.82% from the prior year.
• Free Cash Flow improved to -$9.0 million in Q1 2026, from -$123.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $2.5 million in Q3 2025 to a low of -$166.3 million in Q2 2023.
• A 5-year average of -$87.9 million and a median of -$96.5 million in 2022 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow slumped 103.56% in 2024 and soared 104.12% in 2025, its largest moves.
• Tracing ASND's Free Cash Flow over 5 years: stood at -$139.6 million in 2022, then surged by 67.23% to -$45.8 million in 2023, then sank by 103.56% to -$93.2 million in 2024, then slumped by 32.79% to -$123.7 million in 2025, then jumped by 92.69% to -$9.0 million in 2026.
• Business Quant data shows ASND's Free Cash Flow at -$9.0 million in Q1 2026, -$123.7 million in Q4 2025, and $2.5 million in Q3 2025.